What's New

Medical News
& Alerts

Conferences
& Meetings


Other Medical
Resources

Employment
Opportunities

Partnering
Opportunities

Search results for: IDEC
100%DGNews: Recombinant Factor IX Monomer Formulation Yields Good Results in Patients With Severe Haemophilia B: Presented at Hemophilia 2010
100%DGNews: Study Fails to Demonstrate Efficacy, Safety of Tonapofylline for Decompensated Heart Failure: Presented at Heart Failure 2010
95%DGNews: AAAAI: Preliminary Safety Results Favourable with Antibody Treatment of Seasonal Rhinitis
95%DGNews: PRIMATIZED Monoclonal Antibody Appears Safe and Effective
91%DGNews: Tysabri Multiple Sclerosis Clinical Trial Hold Lifted by FDA; Biogen Idec and Elan to Resume Clinical Trial Dosing in Multiple Sclerosis
91%DGNews: New Safety Information for Amevive (alefacept)
90%DGNews: FDA Approves Resumed Marketing of Tysabri (Natalizumab) Under Special Distribution Program
90%DGNews: Health Canada Approves Amevive (Alefacept), Treatment for Psoriasis
90%DGNews: Amevive (Alefacept), Treatment for Psoriasis, Approved In Australia
90%DGNews: New Drug for Non-Hodgkin's Lymphoma Now Available In The U.S.
90%DGNews: ASH: Zevalin Combination Shows Encouraging Results In NHL
89%DGNews: Tysabri (Natalizumab) Receives Approval in European Union for Treatment of Relapsing Remitting Forms of Multiple Sclerosis
89%DGNews: Clinical Data on Volociximab (M200) Presented at the American Society of Clinical Oncology Annual Meeting
89%DGNews: Amevive (Alefacept), Treatment for Psoriasis, Approved in Israel, Receives 'Positive Opinion' From Swiss Regulatory Authority
89%DGNews: FDA Approves Zevalin (ibritumomab tiuxetan) for Treatment of Non-Hodgkin's Lymphoma
88%DGNews: First New Drug for Non-Hodgkin's Lymphoma in Decade Cleared In U.S.
87%DGNews: Genentech and Biogen Idec Announce Positive Results From a Phase 2 Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis
87%DGNews: Antegren 1-Year Data Show Compelling Results in Meeting Primary Endpoint in Multiple Sclerosis
87%DGNews: ASH: Zevalin (Ibritumomab Tiuxetan) Improves Efficacy Of Rituxan (Rituxumab) In Non-Hodgkin's Lymphoma
87%DGNews: ASH: Radioactive Epratuzumab Shows Promising Results In Aggressive NHL
86%DGNews: FDA Approves TYSABRIŽ (natalizumab) for the Treatment of Moderate-to-Severe Crohn's Disease
86%DGNews: CHMP Issues Positive Opinion for Tysabri (Natalizumab) as a Treatment for Relapsing-Remitting Multiple Sclerosis
86%DGNews: European Commission Approves Zevalin (Ibritumomab tiuxetan) Radioimmunotherapy
85%DGNews: FDA Grants Priority Review for Rituxan (Rituximab) Supplemental Biologics License Application for Front-Line Treatment of Intermediate-Grade or Aggressive Non-Hodgkin's Lymphoma
85%DGNews: Efficacy and Safety of Interferon Beta-1a (Avonex) Appears Unaffected by Gender of Patient: Presented at ECTRIMS
85%DGNews: Recent Study Shows Treatment-Free Periods with New Biologic, Alefacept for Psoriasis
85%DGNews: MabThera Approved In Europe For Non-Hodgkin's Lymphoma
84%DGNews: Intramuscular Interferon Therapy Shows Greater Compliance Than Other Disease-Modifying Therapies: Presented at ENS
84%DGNews: Prednisone, Acetaminophen Equally Effective in Controlling Flulike Symptoms Associated With Interferon-Beta Therapy: Presented at ENS
84%DGNews: FDA Approves Two New Indications for Rituxan(R) (Rituximab) in Patients With Non-Hodgkin's Lymphoma
84%DGNews: Pilot Clinical Study of Genasense (oblimersen sodium) Plus Rituxan and Fludarabine Shows Activity in Chronic Lymphocytic Leukemia
84%DGNews: ASCO: Long-Term Survival For Aggressive Non-Hodgkin's Lymphoma Patients Improved With MabThera Plus Chemotherapy
84%DGNews: ASCO: Rituxan (Rituximab) Plus Fludarabine Effective Front-line Therapy For Chronic Lymphocytic Leukemia
84%DGNews: ASCO MEETING: Rituxan And Fludarabine Effective For NHL Treatment
84%DGNews: ASH: Rituxan, In Combination, Appears Effective For Non-Hodgkin's Lymphoma
83%DGNews: Natalizumab Therapy Significantly Improves Quality of Life in Patients With Highly Active Relapsing MS: Presented at ENS
83%DGNews: FDA Approves Rituxan (Rituximab), the First Targeted B-Cell Therapy for Treatment of Moderate-to-Severe Rheumatoid Arthritis
83%DGNews: ASTRO: Radiolabeled Antibody Safe in Lymphoma Patients Treated With Radiation
82%DGNews: Global Study to Compare Natalizumab, Glatiramer Acetate, and Interferon Beta-1a in Relapsing-Remitting MS
82%DGNews: FDA Approves Rituxan (Rituximab) Plus CHOP or Other Anthracycline-Based Chemotherapy Regimens for First-Line Treatment of Diffuse Large B-cell Non-Hodgkin's Lymphoma
82%DGNews: ASH: MabThera (Rituximab), In Combo Therapy, Shows Positive Response Against Aggressive Non-Hodgkin's Lymphoma
82%DGNews: ASCO: Epratuzumab Promising Against Non-Hodgkin's Lymphoma
80%DGNews: IFN Beta-1a More Effective Over Long Term in Patients at High Risk of Developing MS: Presented at ECTRIMS
80%DGNews: Study Shows Natalizumab (Tysabri) Plus Interferon Beta-1a (Avonex) Reduces Disease Activity: Presented at ECTRIMS
80%DGNews: Not all Interferon-beta Treatments are Created Equal in Developing Neutralizing Antibodies
80%DGNews: Breakthrough MabThera data now shows patients with indolent Non-Hodgkin's Lymphoma can live longer
80%DGNews: FDA Approves Innovative Treatment Tysabri (Natalizumab) - Formerly Antegren - for Multiple Sclerosis:
80%DGNews: ASH MEETING: Over A Quarter Of Rituxan Responders Still In Remission
80%DGNews: New Developments in Monoclonal Antibodies Are Hopeful
79%DGNews: Personalized Cancer Vaccine Improves Disease Free Survival
Enter keywords you wish to find information about:

Search for documents that contain:
any of these words.
this exact phrase.
all of these words.

 

 

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.

All contents Copyright (c) 1998 PSL Consulting Group Inc.
all rights reserved.